8-K: BD Reports Strong FY25 Results, Issues FY26 Guidance

Becton, Dickinson and Company announced robust financial results for its fiscal 2025 fourth quarter and full year, driven by organic growth and significant margin expansion, while also providing its fiscal 2026 outlook.

Summary

• Fourth quarter fiscal 2025 revenue was $5.9 billion, an increase of 8.3% as reported, 7.0% foreign currency neutral (FXN), and 3.9% organic.
• Fourth quarter GAAP diluted EPS grew to $1.72, a 24.6% increase, while adjusted diluted EPS grew to $3.96, a 3.9% increase.
• Full year fiscal 2025 revenue reached $21.8 billion, up 8.2% as reported, 7.7% adjusted FXN, and 2.9% organic.
• Full year GAAP EPS was $5.82, a decrease of 0.7%, while adjusted diluted EPS grew 9.6% to $14.40.
• Full year GAAP gross margin increased by 20 basis points, and adjusted gross margin increased by 140 basis points, primarily driven by BD Excellence initiatives.
• Full year GAAP operating margin decreased 10 basis points to 11.8%, but adjusted operating margin increased 80 basis points to 25.0%.
• The company returned $2.2 billion to shareholders in fiscal 2025 through dividends and share repurchases.
• BD Medical segment achieved 4.0% organic revenue growth, with strong performance in Advanced Patient Monitoring and low single-digit growth in Medication Delivery Solutions, Medication Management Solutions, and Pharmaceutical Systems.
• BD Interventional segment reported 7.5% organic revenue growth, driven by double-digit growth in Urology and Critical Care, high single-digit growth in Surgery, and mid single-digit growth in Peripheral Intervention.
• BD Life Sciences segment saw 0.3% organic revenue growth, with low single-digit growth in Specimen Management and Diagnostic Solutions, partially offset by a decrease in Biosciences.
• The company issued fiscal 2026 guidance, projecting low single-digit plus GAAP revenue growth, low single-digit FXN revenue growth, and adjusted diluted EPS between $14.75 and $15.05.

Sentiment

Score: 8

Explanation: The company reported strong adjusted financial results for fiscal year 2025, including significant revenue and adjusted EPS growth, and substantial margin expansion. It also provided a positive outlook for fiscal year 2026. Strategic initiatives like AI-enabled solutions and the planned combination with Waters Corporation are progressing. While GAAP EPS saw a slight decline and some segments faced headwinds (e.g., China VBP, BDB market dynamics), the overall picture is one of robust operational performance and strategic execution.

Positives

• Strong Q4 FY25 revenue growth of 8.3% reported and 3.9% organic.
• Full year FY25 adjusted diluted EPS grew 9.6% to $14.40.
• Substantial adjusted gross margin (up 140 bps) and adjusted operating margin (up 80 bps) expansion in FY25, attributed to BD Excellence.
• Returned $2.2 billion to shareholders in FY25 through dividends and share repurchases.
• BD Medical segment showed robust organic growth, particularly in Advanced Patient Monitoring.
• BD Interventional segment demonstrated strong organic growth, with double-digit growth in Urology and Critical Care.
• Successful launch of new AI-enabled solutions, including the BD Incada Connected Care Platform and next-generation BD Pyxis Pro Automated Medication Dispensing Solution.
• Established a pharmacy automation partnership with Henry Ford Health utilizing the BD Rowa Vmax robot.
• BD Interventional achieved the Healthcare Industry Resilience Collaborative's (HIRC) Diamond Badge across all seven supply chain resiliency categories, a first in the MedTech industry.
• Reached a major milestone for the Rotarex Catheter System with the first patient enrolled in the XTRACT Registry.
• BD Life Sciences' Diagnostic Solutions returned to positive growth with significant sequential improvement.
• Achieved placement of the 1,000th BD Rhapsody System and announced a collaboration with Opentrons Labworks, Inc. to accelerate single-cell multiomics discoveries.
• Plans to invest approximately $30 million in its Sumter facility in FY26 as part of a five-year investment strategy.

Negatives

• Full year FY25 GAAP EPS decreased 0.7% to $5.82.
• BD Life Sciences Biosciences (BDB) performance decreased due to continued market dynamics impacting research funding.
• Volume-based procurement in China partially offset growth in Medication Delivery Solutions and Peripheral Intervention.
• Lower market demand for vaccine products partially offset growth in Pharmaceutical Systems.
• Full year FY25 GAAP operating margin decreased 10 basis points to 11.8%.
• Net income decreased 1.6% for the full year FY25.
• Cash and equivalents decreased from $1,717 million in FY24 to $641 million in FY25.
• Total assets decreased from $57,286 million in FY24 to $55,325 million in FY25.
• Interest income decreased significantly from $163 million in FY24 to $38 million in FY25.
• Other expense, net, increased substantially from $(28) million in FY24 to $(123) million in FY25.

Risks

• Macroeconomic conditions, including inflationary pressures, currency and interest rate fluctuations, and increased borrowing costs.
• Disruptions in global transportation networks or other aspects of the supply chain affecting raw material sourcing.
• Conditions in international markets, including geopolitical developments in Ukraine, the Middle East, and Asia.
• Competitive factors, such as changing customer and patient preferences, and new products or therapies introduced by competitors.
• Changes in reimbursement practices, coverage policies, and third-party payer cost containment measures.
• Decreases or delays in product purchases due to reduced research and development spending.
• Product efficacy or safety concerns and related regulatory actions, including non-compliance with requirements for products like BD Alaris System, BD Vacutainer, and BD Pyxis.
• Product liability or other claims and potential damage to reputation.
• Changes to legislation or regulations impacting U.S. or foreign healthcare systems, such as China's volume-based procurement tender process.
• Policy and regulatory changes implemented by the U.S. government, including funding reductions for agencies and programs.
• New or changing laws and regulations impacting the business, including tax laws, environmental laws, cybersecurity, AI, and privacy laws.
• Adverse impact from information and technology system disruptions, breaches, or breakdowns, including cyberattacks.
• Risks related to the development, deployment, and use of AI in products and business operations.
• Labor disruptions.
• Suppliers' ability to provide necessary products and BD's ability to maintain favorable supplier arrangements.
• Increases in raw material, component, labor, duties, freight, energy, and other production costs.
• Adverse changes in regional, national, or foreign economic conditions, including access to credit markets.
• Risks relating to overall indebtedness.
• The possible impact of natural disasters and public health crises on business and the global healthcare system.
• Interruptions in manufacturing or sterilization processes, including restrictions on the use of ethylene oxide.
• Pricing and market pressures.
• Difficulties inherent in product development, delays in product introductions, and uncertainty of market acceptance of new products.
• The overall timing of the replacement or remediation of the BD Alaris Infusion System and its return to market in the U.S.
• Ability to achieve projected level or mix of product sales.
• Ability to successfully integrate any acquired businesses.
• Uncertainties of litigation, investigations, regulatory actions, subpoenas, settlements, fines, penalties, and/or other sanctions, including the SEC investigation regarding BD Alaris infusion pumps.
• The issuance of new or revised accounting standards.
• Risks associated with the proposed combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation, including the anticipated benefits and expected timing of completion.

Future Outlook

BD projects low single-digit plus GAAP revenue growth and low single-digit foreign currency neutral (FXN) revenue growth for fiscal year 2026. The company anticipates adjusted diluted EPS for fiscal 2026 to be in the range of $14.75 to $15.05. This outlook is based on current expectations and assumptions regarding various factors affecting the business.

Management Comments

• "Our resilient business model and commitment to commercial and operational execution enabled us to deliver 3.9% organic growth in New BD along with substantial adjusted margin and earnings growth in fiscal 2025."
• "We remain on track to complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar year 2026."
• "New BD will be a leading Med Tech company making a profound impact on health care and patients worldwide. By focusing on growth in attractive markets and executing BD Excellence, we are driving stronger margins, earnings expansion and long-term value."

Industry Context

BD operates within the dynamic global medical technology sector. The company's strategic focus on AI-enabled solutions, pharmacy automation, and single-cell multiomics discoveries aligns with broader industry trends towards digital transformation, enhanced efficiency, and advanced diagnostics. The mention of volume-based procurement in China highlights ongoing pricing pressures and market complexities in certain international regions, a common challenge for MedTech companies. The proposed combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation indicates a strategic portfolio optimization aimed at focusing on core growth areas and enhancing market position within the MedTech landscape.

Comparison to Industry Standards

• BD Interventional's Urology and Critical Care (UCC) and Surgery business units are the first in the MedTech industry to achieve the Healthcare Industry Resilience Collaborative's (HIRC) Diamond Badge across all seven supply chain resiliency categories, indicating a leading position in supply chain management.

Corporate Governance

Legal Proceedings

• For the three months ended September 30, 2025, charges of $232 million were recorded to Other operating expense, net, related to product liability and certain other legal matters.
• For the twelve months ended September 30, 2025, charges of $297 million were recorded to Other operating expense, net, related to product liability and certain other legal matters.
• For the three months ended September 30, 2024, a $125 million charge was accrued for an estimated liability related to an SEC investigation concerning reporting issues involving BD Alaris™ infusion pumps prior to 2021.
• For the twelve months ended September 30, 2024, a $175 million charge was accrued for an estimated liability related to the SEC investigation concerning reporting issues involving BD Alaris™ infusion pumps prior to 2021.
• Recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, substantially related to years prior to fiscal year 2024, impacting revenues by $67 million in FY24.

Stakeholder Impact

• Shareholders: Positive impact due to strong adjusted earnings growth, significant margin expansion, $2.2 billion returned through dividends and share repurchases, and positive FY26 guidance.
• Employees: Continued investment in manufacturing sites (e.g., Sumter facility) and strategic growth initiatives suggest stability and potential for growth opportunities.
• Customers: Benefit from new AI-enabled solutions, pharmacy automation partnerships, and expanded access to cervical cancer screening solutions, enhancing healthcare delivery and diagnostics.
• Suppliers: Potential for continued business given BD's operational scale and focus on supply chain resilience, but also subject to ongoing cost management and efficiency drives.
• Creditors: Overall strong financial health and positive outlook support creditworthiness, despite significant long-term debt obligations.

Next Steps

• Complete the combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar year 2026.
• Invest approximately $30 million in the Sumter facility in fiscal year 2026 as part of its previously announced five-year investment strategy.
• Continue to drive stronger margins, earnings expansion, and long-term value by focusing on growth in attractive markets and executing BD Excellence.

Key Dates

Recommendation

BD delivered robust adjusted financial performance in fiscal year 2025, marked by strong revenue growth, significant adjusted EPS expansion, and impressive margin improvements driven by operational excellence. The company's strategic initiatives, including the launch of AI-enabled solutions and the planned combination of its Biosciences and Diagnostic Solutions business, position it for continued innovation and market leadership. The positive fiscal year 2026 guidance further reinforces confidence in future earnings and growth. Despite some GAAP-level headwinds and ongoing legal/regulatory costs, the underlying operational strength and commitment to shareholder returns make BD an attractive investment.

Keywords

Medical Technology, Healthcare, Financial Results, Earnings, Revenue, EPS, Gross Margin, Operating Margin, Dividends, Share Repurchases, Medication Management, Diagnostic Solutions, Biosciences, Interventional, Supply Chain, AI-enabled solutions, Peripheral Artery Disease, Cervical Cancer Screening, Single-cell Multiomics, FY25, FY26 Guidance, BDX